
Opinion|Videos|November 12, 2024
New Data from AANEM 2024 in Generalized Myasthenia Gravis
Key Takeaways
- Gene therapy advancements for inherited neuromuscular disorders were a significant focus, highlighting potential transformative impacts on treatment paradigms.
- Novel pharmacological interventions targeting specific molecular pathways showed promise, indicating a shift towards more targeted therapeutic approaches.
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.
Advertisement
Video content above is prompted by the following:
- Please share other interesting/practice-impacting data that were presented at AANEM 2024.
- What other emerging treatments are you excited about?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup
2
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
3
Ractigen Completes Enrollment for RAG-17 in SOD1-ALS, Tanruprubart Shows Rapid Responses in GBS, Building a Multidisciplinary SMA Clinic
4
CN045 Promotes Oligodendrocyte Maturation, Modest Remyelination in Preclinical MS Study
5











